<DOC>
	<DOCNO>NCT01136408</DOCNO>
	<brief_summary>The primary objective evaluate safety dabigatran etexilate ( BIBR 1048 ) administer orally dose 110 150 mg , twice daily , 12 week patient non-valvular atrial fibrillation ( paroxysmal , persistent permanent ) comparison warfarin .</brief_summary>
	<brief_title>A Dose Response Study Dabigatran Etexilate ( BIBR 1048 ) Pharmacodynamics Safety Patients With Non-valvular Atrial Fibrillation Comparison Warfarin</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Inclusion criterion Inclusion criterion 1 . Patients nonvalvular atrial fibrillation ( paroxysmal , persistent permanent ) 2 . Patients additional risk factor thromboembolism ; one follow conditions/events : Hypertension Diabetes mellitus Leftside heart failure A previous ischemic stroke transient ischemic attack Age 75 year old A history coronary artery diseases Exclusion criterion Exclusion criterion 1 . Patients diagnose valvular heart disease echocardiography , patient history prosthetic valve replacement valve surgery 2 . Patients receive electric defibrillation pharmacological defibrillation study period 3 . Patients develop stroke transient ischemic attack within 30 day date inform consent 4 . Patients develop myocardial infarction admit hospital due acute coronary syndrome percutaneous transluminal coronary angioplasty within 3 month date inform consent patient underwent coronary stenting within 6 month date inform consent 5 . Patients atrial myxoma leave ventricular thrombosis 6 . Patients contraindication anticoagulant therapy 7 . Patients schedule major surgery invasive procedure 8 . Patients major bleed nongastrointestinal organ within 6 month date inform consent 9 . Patients uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>